Presentation is loading. Please wait.

Presentation is loading. Please wait.

Postprandial glucose flux in nondiabetic controls.

Published byEgbert Richard Modified over 6 years ago

Similar presentations

Presentation on theme: "Postprandial glucose flux in nondiabetic controls."— Presentation transcript:

1 Postprandial glucose flux in nondiabetic controls.
Postprandial glucose flux in nondiabetic controls. Postprandial glucose flux is a balance between glucose appearance in the circulation and glucose disappearance or uptake. Glucose appearance is a function of hepatic (endogenous) glucose production and meal-derived sources and is regulated by pancreatic and gut hormones. Glucose disappearance is insulin mediated. Calculated from data in the study by Pehling et al.26 Stephen L. Aronoff et al. Diabetes Spectr 2004;17: ©2004 by American Diabetes Association

Download ppt "Postprandial glucose flux in nondiabetic controls."

Similar presentations

Philip J. Barter, et al. Circulation 2011;124:555-562.

Philip J. Barter, et al. Circulation 2011;124:
JANUVIA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. JANUVIA Tablets contain sitagliptin.

JANUVIA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. JANUVIA Tablets contain sitagliptin.
Contributions to Type 2 Diabetes. Glucose in balance meal Time in minutes Blood glucose levels, mg/dL -60 0 60 120 180 240 80 Insulin levels, uU/mL Glucagon.

Contributions to Type 2 Diabetes. Glucose in balance meal Time in minutes Blood glucose levels, mg/dL Insulin levels, uU/mL Glucagon.
Glucose Metabolism Dr Lenon T Gwaunza MBChB, BSc (Hons), MSc (UCL)

Glucose Metabolism Dr Lenon T Gwaunza MBChB, BSc (Hons), MSc (UCL)
Stages in the development of type 2 DM from a pre-diabetic, insulin-resistant state. As insulin sensitivity decreases, insulin-mediated glucose disposal.

Stages in the development of type 2 DM from a pre-diabetic, insulin-resistant state. As insulin sensitivity decreases, insulin-mediated glucose disposal.
Mean rates of insulin and glucagon delivery from an artificial pancreas at various blood glucose levels. The device was programmed to establish and maintain.

Mean rates of insulin and glucagon delivery from an artificial pancreas at various blood glucose levels. The device was programmed to establish and maintain.
Figure 2 Pathophysiology of hyperglycaemia in T2DM

Figure 2 Pathophysiology of hyperglycaemia in T2DM
Glucose homeostasis: roles of insulin and glucagon. 1A.

Glucose homeostasis: roles of insulin and glucagon. 1A.
Insulin and glucagon secretion: nondiabetic and diabetic subjects.

Insulin and glucagon secretion: nondiabetic and diabetic subjects.
Glycemic response to a pizza meal illustrated on a line graph (DexCom Data Manager 2 Software). Glycemic response to a pizza meal illustrated on a line.

Glycemic response to a pizza meal illustrated on a line graph (DexCom Data Manager 2 Software). Glycemic response to a pizza meal illustrated on a line.
Glucose homeostasis: roles of insulin, glucagon, amylin, and GLP-1.

Glucose homeostasis: roles of insulin, glucagon, amylin, and GLP-1.
Figure 1 Regulation of hepatic glucose metabolism by the gut, brain and liver Figure 1 | Regulation of hepatic glucose metabolism by the gut, brain and.

Figure 1 Regulation of hepatic glucose metabolism by the gut, brain and liver Figure 1 | Regulation of hepatic glucose metabolism by the gut, brain and.
Impact of U-100 RHI administered with V-Go at OV1 (3 months after initiation) and OV2 (6 months after initiation) (n = 11) at 3 months (P = 0.32) and at.

Impact of U-100 RHI administered with V-Go at OV1 (3 months after initiation) and OV2 (6 months after initiation) (n = 11) at 3 months (P = 0.32) and at.
Patient flow chart: the final prospective study population consisted of 521 individuals, 113 on basal insulin and 408 on OADs. *Plausibility: height (130–230 cm),

Patient flow chart: the final prospective study population consisted of 521 individuals, 113 on basal insulin and 408 on OADs. *Plausibility: height (130–230 cm),
GLP-1 Agonists and DPP-4 Inhibitors How do they work?

GLP-1 Agonists and DPP-4 Inhibitors How do they work?
A whole body model for both glucose and fatty acid metabolism

A whole body model for both glucose and fatty acid metabolism
Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.
HOMA calculations where glucose is mmol/L and insulin is mU/L

HOMA calculations where glucose is mmol/L and insulin is mU/L
Evolution of Insulin: From Human to Analog

Evolution of Insulin: From Human to Analog
Whole-body glucose kinetics in C and T2D-O during postabsorptive and clamp states. Whole-body glucose kinetics in C and T2D-O during postabsorptive and.

Whole-body glucose kinetics in C and T2D-O during postabsorptive and clamp states. Whole-body glucose kinetics in C and T2D-O during postabsorptive and.

Similar presentations

Ads by Google